Innovating During COVID-19: New Jersey’s Next Era in Life Sciences
Posted Monday, August 17, 2020
“Following 150 years of global leadership in life sciences, cell and gene therapy (CGT) is rapidly accelerating within the New Jersey ecosystem.
As winter began to wane this year, the world was upended by the COVID-19 pandemic. Unprecedented levels of interest in cell and gene therapies have followed, with research and development (R&D) facilities testing different potential solutions, such as immunoglobulin plasma treatments as part of vaccine trials. At the heart of these efforts, New Jersey’s biopharma industry has played a key role, inspiring collaboration, conducting research, and driving innovation.”